Financhill
Sell
33

BNTX Quote, Financials, Valuation and Earnings

Last price:
$105.44
Seasonality move :
11.32%
Day range:
$105.61 - $110.00
52-week range:
$76.53 - $131.49
Dividend yield:
0%
P/E ratio:
191.55x
P/S ratio:
8.67x
P/B ratio:
1.25x
Volume:
687.1K
Avg. volume:
1.1M
1-year change:
9.09%
Market cap:
$25.7B
Revenue:
$3B
EPS (TTM):
-$3.40

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BNTX
BioNTech SE
$183.4M -$2.66 21.79% -47.38% $133.89
ADAP
Adaptimmune Therapeutics PLC
$6.6M -$0.17 -91.39% -8.33% $1.58
AUTL
Autolus Therapeutics PLC
$2M -$0.25 -80.39% -10.73% $9.86
MRNA
Moderna
$115.3M -$3.11 -49.84% -11.55% $47.64
NCNA
NuCana PLC
-- -$0.01 -- -99.69% $104.00
NVAX
Novavax
$343.9M $1.41 -67.66% -82.16% $14.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BNTX
BioNTech SE
$106.89 $133.89 $25.7B 191.55x $0.00 0% 8.67x
ADAP
Adaptimmune Therapeutics PLC
$0.28 $1.58 $73.5M -- $0.00 0% 0.40x
AUTL
Autolus Therapeutics PLC
$2.33 $9.86 $620.1M -- $0.00 0% --
MRNA
Moderna
$27.68 $47.64 $10.7B -- $0.00 0% 3.43x
NCNA
NuCana PLC
$0.14 $104.00 $869.2K -- $0.00 0% --
NVAX
Novavax
$7.20 $14.67 $1.2B 2.72x $0.00 0% 0.98x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BNTX
BioNTech SE
1.53% 1.010 1.45% 9.86x
ADAP
Adaptimmune Therapeutics PLC
-211.44% 3.737 50.03% 1.57x
AUTL
Autolus Therapeutics PLC
-- 2.244 -- 8.74x
MRNA
Moderna
-- -0.658 -- 3.92x
NCNA
NuCana PLC
-- -3.655 -- --
NVAX
Novavax
180.06% 1.623 16.39% 1.84x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BNTX
BioNTech SE
$104.2M -$562M -3.86% -3.91% -225.11% -$1.5B
ADAP
Adaptimmune Therapeutics PLC
$6.4M -$44.1M -107.36% -199.63% -619.47% -$67.8M
AUTL
Autolus Therapeutics PLC
-$9M -$65.2M -49.92% -49.92% -643.43% -$83.8M
MRNA
Moderna
$17M -$1.1B -29.23% -29.23% -900% -$1.2B
NCNA
NuCana PLC
-- -$3.5M -- -- -- -$4M
NVAX
Novavax
$612.2M $515.5M -- -- 83.91% -$187.1M

BioNTech SE vs. Competitors

  • Which has Higher Returns BNTX or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -227.46% compared to BioNTech SE's net margin of -653.18%. BioNTech SE's return on equity of -3.91% beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    ADAP
    Adaptimmune Therapeutics PLC
    87.93% -$0.18 -$12M
  • What do Analysts Say About BNTX or ADAP?

    BioNTech SE has a consensus price target of $133.89, signalling upside risk potential of 25.26%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.58 which suggests that it could grow by 468.43%. Given that Adaptimmune Therapeutics PLC has higher upside potential than BioNTech SE, analysts believe Adaptimmune Therapeutics PLC is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 5 0
    ADAP
    Adaptimmune Therapeutics PLC
    3 3 0
  • Is BNTX or ADAP More Risky?

    BioNTech SE has a beta of 1.288, which suggesting that the stock is 28.759% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.243, suggesting its more volatile than the S&P 500 by 124.255%.

  • Which is a Better Dividend Stock BNTX or ADAP?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or ADAP?

    BioNTech SE quarterly revenues are $192.3M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. BioNTech SE's net income of -$437.5M is lower than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.67x versus 0.40x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.67x 191.55x $192.3M -$437.5M
    ADAP
    Adaptimmune Therapeutics PLC
    0.40x -- $7.3M -$47.6M
  • Which has Higher Returns BNTX or AUTL?

    Autolus Therapeutics PLC has a net margin of -227.46% compared to BioNTech SE's net margin of -781.13%. BioNTech SE's return on equity of -3.91% beat Autolus Therapeutics PLC's return on equity of -49.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    AUTL
    Autolus Therapeutics PLC
    -99.86% -$0.26 $371.1M
  • What do Analysts Say About BNTX or AUTL?

    BioNTech SE has a consensus price target of $133.89, signalling upside risk potential of 25.26%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 322.99%. Given that Autolus Therapeutics PLC has higher upside potential than BioNTech SE, analysts believe Autolus Therapeutics PLC is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 5 0
    AUTL
    Autolus Therapeutics PLC
    8 0 0
  • Is BNTX or AUTL More Risky?

    BioNTech SE has a beta of 1.288, which suggesting that the stock is 28.759% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.756, suggesting its more volatile than the S&P 500 by 75.594%.

  • Which is a Better Dividend Stock BNTX or AUTL?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or AUTL?

    BioNTech SE quarterly revenues are $192.3M, which are larger than Autolus Therapeutics PLC quarterly revenues of $9M. BioNTech SE's net income of -$437.5M is lower than Autolus Therapeutics PLC's net income of -$70.2M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.67x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.67x 191.55x $192.3M -$437.5M
    AUTL
    Autolus Therapeutics PLC
    -- -- $9M -$70.2M
  • Which has Higher Returns BNTX or MRNA?

    Moderna has a net margin of -227.46% compared to BioNTech SE's net margin of -907.48%. BioNTech SE's return on equity of -3.91% beat Moderna's return on equity of -29.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    MRNA
    Moderna
    15.89% -$2.52 $10.1B
  • What do Analysts Say About BNTX or MRNA?

    BioNTech SE has a consensus price target of $133.89, signalling upside risk potential of 25.26%. On the other hand Moderna has an analysts' consensus of $47.64 which suggests that it could grow by 72.1%. Given that Moderna has higher upside potential than BioNTech SE, analysts believe Moderna is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 5 0
    MRNA
    Moderna
    4 17 1
  • Is BNTX or MRNA More Risky?

    BioNTech SE has a beta of 1.288, which suggesting that the stock is 28.759% more volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

  • Which is a Better Dividend Stock BNTX or MRNA?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or MRNA?

    BioNTech SE quarterly revenues are $192.3M, which are larger than Moderna quarterly revenues of $107M. BioNTech SE's net income of -$437.5M is higher than Moderna's net income of -$971M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.67x versus 3.43x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.67x 191.55x $192.3M -$437.5M
    MRNA
    Moderna
    3.43x -- $107M -$971M
  • Which has Higher Returns BNTX or NCNA?

    NuCana PLC has a net margin of -227.46% compared to BioNTech SE's net margin of --. BioNTech SE's return on equity of -3.91% beat NuCana PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    NCNA
    NuCana PLC
    -- -$0.63 --
  • What do Analysts Say About BNTX or NCNA?

    BioNTech SE has a consensus price target of $133.89, signalling upside risk potential of 25.26%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 72373.87%. Given that NuCana PLC has higher upside potential than BioNTech SE, analysts believe NuCana PLC is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 5 0
    NCNA
    NuCana PLC
    0 1 0
  • Is BNTX or NCNA More Risky?

    BioNTech SE has a beta of 1.288, which suggesting that the stock is 28.759% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.98%.

  • Which is a Better Dividend Stock BNTX or NCNA?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or NCNA?

    BioNTech SE quarterly revenues are $192.3M, which are larger than NuCana PLC quarterly revenues of --. BioNTech SE's net income of -$437.5M is lower than NuCana PLC's net income of -$3.1M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.67x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.67x 191.55x $192.3M -$437.5M
    NCNA
    NuCana PLC
    -- -- -- -$3.1M
  • Which has Higher Returns BNTX or NVAX?

    Novavax has a net margin of -227.46% compared to BioNTech SE's net margin of 82.81%. BioNTech SE's return on equity of -3.91% beat Novavax's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
    NVAX
    Novavax
    97.75% $2.93 $94.5M
  • What do Analysts Say About BNTX or NVAX?

    BioNTech SE has a consensus price target of $133.89, signalling upside risk potential of 25.26%. On the other hand Novavax has an analysts' consensus of $14.67 which suggests that it could grow by 103.7%. Given that Novavax has higher upside potential than BioNTech SE, analysts believe Novavax is more attractive than BioNTech SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    BNTX
    BioNTech SE
    13 5 0
    NVAX
    Novavax
    3 2 0
  • Is BNTX or NVAX More Risky?

    BioNTech SE has a beta of 1.288, which suggesting that the stock is 28.759% more volatile than S&P 500. In comparison Novavax has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.302%.

  • Which is a Better Dividend Stock BNTX or NVAX?

    BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BNTX or NVAX?

    BioNTech SE quarterly revenues are $192.3M, which are smaller than Novavax quarterly revenues of $626.3M. BioNTech SE's net income of -$437.5M is lower than Novavax's net income of $518.6M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Novavax's PE ratio is 2.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.67x versus 0.98x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BNTX
    BioNTech SE
    8.67x 191.55x $192.3M -$437.5M
    NVAX
    Novavax
    0.98x 2.72x $626.3M $518.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will VICI Properties Be in 5 Years?
Where Will VICI Properties Be in 5 Years?

VICI Properties (NYSE:VICI) is a real estate investment trust focused…

Where Will Exxon Stock Be in 5 Years?
Where Will Exxon Stock Be in 5 Years?

For sure Exxon Mobil (NYSE: XOM) is no hyped-up AI…

How High Will Dollar General Stock Go?
How High Will Dollar General Stock Go?

Shares of Dollar General (NYSE:DG) have risen significantly in recent…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
75
INSM alert for Jun 11

Insmed [INSM] is up 7.75% over the past day.

Sell
25
AAON alert for Jun 11

AAON [AAON] is down 3.49% over the past day.

Buy
58
EXOD alert for Jun 11

Exodus Movement [EXOD] is down 8.21% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock